Nasopharyngeal carcinoma in childhood and adolescence

Serin, M.; Erkal, Haldun Şükrü; Elhan, Atilla Halil; Çakmak, Ahmet

doi:10.1002/(sici)1096-911x(199812)31:6<498::aid-mpo6>3.3.co;2-f

Cited by 11 publications

(20 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Higher RT doses were used in the recent era, and RT≥50Gy to primary tumor or nodal sites was associated with lower distant failure and better EFS. Similar association between RT dose and survival has been previously reported 5, 13, 14, 21, 23. The switch from cyclophosphamide-based to cisplatin-based chemotherapy in the most recent era might also contribute to improved outcome; patients who received cisplatin had lower incidence of distant failure and better EFS, consistent with the recent report by Kupeli 20.…”

Section: Discussionsupporting

confidence: 88%

Prognostic factors and long‐term outcomes of childhood nasopharyngeal carcinoma

Cheuk

Billups

Martin

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:The authors studied the survival and long-term morbidities of children with nasopharyngeal carcinoma (NPC). METHODS: This was a retrospective review of children with NPC who were treated at St. Jude Children's Research Hospital between 1961 and 2004. Prognostic factors and long term effects of therapy were analyzed. RESULTS: Fifty-nine patients (median age, 14.1 years) were identified. Most were male (66.1%) and black (54.2%) and had lymphoepithelioma (93.2%). Thirty-five patients had stage IV disease (59.3%), 20 patients had stage III disease (33.9%), and 4 patients had stage II disease (6.8%). All patients received radiotherapy (RT) to the primary tumor, and most received cervical RT (98.3%) and chemotherapy (88.1%). The 15-year survival and event-free survival (EFS) rates were 67.2% AE 7.5% and 63.5% AE 7.8%, respectively. Five patients (8.5%) developed subsequent malignancies 8.6 to 27 years after NPC diagnosis. EFS was improved in patients who were diagnosed after 1980 (74.8% AE 10% vs 45.5% AE 10.1%; P ¼ .031), in patients who had stage III disease compared with patients who had stage IV disease (79.3% AE 9.6% vs 56.2% AE 11.8%; P ¼ .049), in patients who received cisplatin (81% AE 10.7% vs 45.8% AE 9.7%; P ¼ .013), and in patients who received !50 grays of RT (71.4% AE 9.3% vs 43.8% AE 11.6%; P ¼ .048). White patients had higher distant failure rates than black patients (41.7% AE 10.4% vs 15.6 AE 6.5%; P ¼ .045). The 15-year cumulative incidence (CI) of any morbidity was 83.7% AE 5.4%, the CI of sensorineural hearing loss was 52.9% AE 6.7%, the CI of primary hypothyroidism was 42.7% AE 6.6%, and the CI of growth hormone deficiency (GHD) was 14.1% AE 4.7%. Dose-response relations were observed between the RT dose and primary hypothyroidism and GHD. CONCLUSIONS: The outcome of children with NPC improved over the past 4 decades with the use of cisplatin-based chemotherapy and higher RT doses. However, many survivors had long-term treatment-related morbidities.

show abstract

Section: Discussionsupporting

confidence: 88%

Prognostic factors and long‐term outcomes of childhood nasopharyngeal carcinoma

Cheuk

Billups

Martin

et al. 2010

Cancer

View full text Add to dashboard Cite

show abstract

“…There is a signifi cant number of reports in the literature which reported the treatment results of pediatric and adolescent NPC patients from the Maghrep countries, Egypt, Israel, and Turkey (Serin et al 1998;Har-Kedar et al 1974). There is a signifi cant number of reports in the literature which reported the treatment results of pediatric and adolescent NPC patients from the Maghrep countries, Egypt, Israel, and Turkey (Serin et al 1998;Har-Kedar et al 1974).…”

Section: Etiological and Epidemiological Featuresmentioning

confidence: 99%

Nasopharyngeal Cancer

Lu¹,

Js²,

Lee³

2010

Medical Radiology

View full text Add to dashboard Cite

“…Ainsi, de nombreuses équipes associentelles de la chimiothérapie avant la radiothérapie afin d'obtenir un meilleur contrôle local, de stériliser d'éventuelles micrométastases et d'améliorer le pronostic global [12,25]. Les autres médicaments connus pour être les plus efficaces dans cette pathologie sont la doxorubicine, la bléomycine, le 5-fluorouracil et les alcaloïdes de la pervenche [6,12,18,20,[26][27][28][29][30][31][32]. Néanmoins, aucune étude randomisée n'a pu faire la preuve scientifique de sa nécessité chez l'enfant en raison du petit nombre de patients concernés.…”

Section: Chimiothérapieunclassified

“…Certains auteurs trouvent une amélioration de la survie avec des doses plus élevées délivrées au cavum, la plupart du temps supérieur à 65 Gy [26] tandis que d'autres équipes ne notent, seulement qu'une tendance à une meilleure survie [37]. Chez les patients adultes, des doses plus élevées (> 70 Gy) pourraient être plus efficaces [38].…”

Section: Irradiation Du Cavumunclassified

“…Toutes portent sur des petits nombre patients (entre 16 et 60 enfants) mais montrent une amélioration historique du contrôle local et la survie en utilisant une chimiothérapie première avec les techniques modernes de radiothérapie [26,41,42]. Elles montrent des survies sans récidive parfois supérieure à 90 % à 32 mois, chez des enfants ou des adolescents même porteurs d'une tumeur à un stade localement avancé.…”

Section: Chimiothérapieunclassified

See 1 more Smart Citation